Outlook Therapeutics appoints Dr. Julia A. Haller to board, increases size to 10

Outlook Therapeutics, Inc.

Board expanded from 9 to 10 members; Dr. Haller appointed as Class II director effective Aug 11, 2022.
Dr. Haller replaces Randy Thurman on Nominating and Corporate Governance Committee; Thurman stays on board.
Received option for 25,000 shares at $1.15 (Aug 11 close), vesting over 3 years under 2015 Equity Incentive Plan.
Standard indemnification agreement entered; compensation per non-employee director policy.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Julia A. Haller

Director

OTLK · Outlook Therapeutics, Inc.

Effective: 2022-08-11
Filed: August 15, 2022, 7:59 PM ET

appointed Dr. Julia A. Haller to fill the newly created vacancy

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Julia A. Haller was appointed as Director at Outlook Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

appointed Dr. Julia A. Haller to fill the newly created vacancy

View on SEC.gov

Outlook Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-091217

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.